GlucoModicum

Needle-free glucose monitoring (Sofio) using magnetohydrodynamics (MHD) — magnetic sampling of dermal interstitial fluid into an electrochemical sensor, ~13× better than reverse iontophoresis. Clinical study MARD 11.5% (approaching needle-based CGM). Univ. Helsinki spinout 2018 (Boeva, Perez, Bobacka); working toward EU CE mark.

The row

Sector

Medtech & Digital Health

Stage

Pre-revenue — No sales yet

Location

Helsinki

Founded

2018

Research origin

Univ. of Helsinki + Åbo Akademi

Business ID

2900506-7 · Finnish trade register

Funding

€1.2M+ seed (Finnish medtech investors + Business Finland, over-subscribed); later rounds not itemised publicly. Investors incl. Proxy Ventures, European Innovation Council, European Investment Bank

Links

Where this sits on the map

GlucoModicum is one of 33 companies in Medtech & Digital Health. The others:

How this row was decided

Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗